Studies with both agents at different concentrations showed synergistic results in ovarian cancer cell lines (OVCAR8, OVCAR3 and IGROV1), triple negative (HS‐578T, HCC3153 and MDA‐MB‐231), and the HER2‐positive BT474 (Figure 5B). This evidence concerns the gene ERBB2 and ovarian cancer.